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Loss of chromosome arm 18q is a common event in human pancreatic, colon, and breast cancers and is often interpreted as
representing loss of one or more tumor-suppressor genes. In this article, we describe two novel biallelic deletions at chromo-
some band 18q21.1 in a recently characterized human breast cancer cell line, HCC-1428. One lesion deletes a fragment of
approximately 300 kb between SMAD4 and DCC that encodes no known genes. The second lesion is an in-frame SMAD4 dele-
tion (amino acids 49–51) that affects the level of SMAD4 protein but not the SMAD4 message. This change accelerates 26S
proteasome–mediated degradation of both endogenous and exogenous mutant SMAD4. Examination of normal DNA from
the same patient demonstrated that both lesions are somatic and associated with loss of both normal alleles. These data sup-
port the concept that two independent tumor-suppressor loci exist at chromosome segment 18q21.1, one at SMAD4 and the
other potentially at an enhancer of DCC or an unrelated novel gene. ' 2005 Wiley-Liss, Inc.
INTRODUCTION
Breast cancer was responsible for the deaths of
an estimated 40,200 women in 2003 just in the
United States (Ries et al., 2003). Unfortunately,
many of the genetic causes of this devastating dis-
ease remain unknown. Cancer geneticists have
long labored to discover the tumor suppressors
and oncogenes altered in breast carcinoma. One
approach to identifying novel tumor suppressors
has been to characterize biallelic deletions (also
known as homozygous deletions) in the genomes
of cancer cell lines and xenografts. This strategy
proved indispensable for the positional cloning of
tumor- suppressor genes including RB1 (Lee et al.,
1987), CDKN2A (Kamb et al., 1994), SMAD4 (Hahn
et al., 1996b), and PTEN (Li et al., 1997). With the
human genome project now complete, biallelic
deletions should prove easier to map and candidate
tumor-suppressor genes easier to identify.
Representational difference analysis (RDA)
allows an investigator to perform a genomewide,
unbiased screen for biallelic deletions (Lisitsyn
and Wigler, 1993). RDA, a PCR-based subtraction-
hybridization technique, was integral to the iden-
tiﬁcation of the biallelic deletions utilized to
clone the candidate tumor suppressors PTEN (Li
et al., 1997), LRP1B (Liu et al., 2000), and
BRCA2 (Schutte et al., 1995).
This study employed RDA in a screen for bial-
lelic deletions in the genome of the recently iso-
lated breast cancer cell line HCC-1428. RDA
uncovered one novel biallelic deletion in the
HCC-1428 genome, on the 18q21.1 chromosome
segment. We were able to demonstrate that the
biallelic deletion does not alter the open-reading
frames (ORFs) of the SMAD4 or DCC candidate
tumor-suppressor genes, also on chromosome seg-
ment 18q21.1. We mapped the extent of the dele-
tion, determined its length as 260–330 kbp, and
localized it as being between the SMAD4 and DCC
loci. Sequence analysis of the SMAD4 gene in the
HCC-1428 cell line identiﬁed only an allele with a
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novel in-frame and protein destabilizing mutation
whose predicted effect was to delete amino acids
49–51 of the MH1 domain. The existence of a sec-
ond biallelic deletion of approximately 300 kilo-
base pairs (kbp) between the SMAD4 and DCC
genes suggests the potential to select for loss of an




Human breast carcinoma cell lines MDA-MB-
468, MDA-MB-415, MDA-MB-474, MDA-MB-453,
MCF7, and T-47D, human colorectal carcinoma cell
line SW-480, human glioblastoma cell line U-87,
and the African green monkey kidney, SV40-trans-
formed COS-1 cell line were acquired from the
American Type Culture Collection (ATCC) (Mana-
ssas, VA) and cultured according to the distributor’s
instructions. Human mammary epithelial cells
(HMEC) were purchased from Clonetics (San
Diego, CA) and cultured per the distributor’s
instructions. The Gazdar laboratory isolated breast
carcinoma cell lines HCC-1428, HCC-1428 BL,
HCC-1937, and HCC-1143; they are now available
from the ATCC (Gazdar et al., 1998).
Representational Difference Analysis
Representational difference analysis (RDA) was
performed essentially as described by Lisitsyn and
Wigler (1993). Speciﬁcally, the HCC-1428 genome
served as the ‘‘driver genome,’’ or template for the
driver; the HCC-1428 BL genome as the ‘‘tester
genome,’’ or template for the tester. BglII restric-
tion endonuclease (New England Biolabs, Beverly,
MA) was employed to construct the driver and the
tester. Our RDA methodology did differ from the
original protocols in the ratio of driver to tester that
was used for subtraction-hybridization. To set up
the ﬁrst-round subtraction-hybridization reaction,
driver and tester were mixed in an 80:1 ratio (40 mg
driver:500 ng tester). For the second-round sub-
traction-hybridization, an 800:1 ratio was employed
(40 mg driver:50 ng tester). In the third-round sub-
traction-hybridization, driver and tester were
mixed in a 400,000:1 ratio (40 mg driver:100 pg
tester).
Screening Products of Representational Difference
Analysis of the HCC-1428 Genome for Deleted
Sequences
RDA products were cloned into the pZeroII
vector (Invitrogen, Carlsbad, CA) using the
BamHI site, electroporated into DH10B E. coli.
(Invitrogen), and 800 colonies were selected for
sequencing. We performed all sequencing in this
study on the ABI Prism 377 DNA sequencer
(Applied Biosystems, Foster City, CA). In a PCR
screen for deleted fragments, the HCC-1428 BL
genome was used as the template for a positive
control reaction.
Polymerase Chain Reaction
All polymerase chain reactions (PCR) in this
study were performed under the following condi-
tions unless otherwise indicated: 10 mL volume
with 16.6 mM (NH)2 SO4, 67 mM Tris-HCl (pH
8.8), 6.7 mM MgCl2, 10 mM 2-mercaptoethanol,
0.25 mM dNTPs, 6% DMSO, 350 ng of each pri-
mer, and 0.5 U of Platinum Taq (GibcoBRL, Carls-
bad, CA). PCR reactions were performed on 10 ng
of genomic DNA. All PCR reactions were car-
ried out on a Hybaid Omnigene Thermocycler
(Thermo Electron Corporation, Waltham, MA).
PCR primers used in this study are available on
request.
Bacterial Artiﬁcial Chromosome Isolation and
End Sequencing
The sequence-tagged site (STS) SHGC-7133
was used to PCR-screen the Human Bacterial Arti-
ﬁcial Chromosome Release II Library (Genome
Systems, St. Louis, MO). We used a NucleoBond
Plasmid Kit (Clontech, Palo Alto, CA) to isolate
bacterial artiﬁcial chromosomes (BACs) 494J9 and
471M4. SP6 and T7 primers were used to
sequence BAC ends.
Sequence-Tagged Site Mapping
PCR conditions and primers for sequence-
tagged sites used in this study are available on
request as are STS coordinates on the NCBI chro-
mosome 18 contig (accession no. NT_010966.13,
October 17, 2003, version). PCR products of novel
STSs probe B, 84-2, 494J9-T7, rpS8-like EST,
800-20K, and 494J9-SP6 were sequenced directly
in order to conﬁrm their identities. The control
PCR fragment was from chromosome 2, NCBI




(SNPs) in the deleted region were identiﬁed with
the NCBI dbSNP database and PCR-ampliﬁed
from the HCC-1428 BL genome. Sequence analy-
sis of candidate SNP PCR products demonstrated
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that rs2615548 was present in two variants in the
HCC-1428 BL genome. An ambiguous nucleotide
(peaks at both G and T), referred to as N, was
detected at the predicted rs2615548 SNP position.
To conﬁrm that both the G and T alleles were
ampliﬁed from the HCC-1428 BL genome, this
PCR product was cloned into the pZeroII vector,
and individual clones were sequenced. The G and
T alleles were detected with equal frequency.
Results were conﬁrmed with a second rs2615548
SNP PCR ampliﬁcation from the HCC-1428 BL
genome and subsequent product sequencing. The
control PCR fragment also was from chromo-
some 2, NCBI accession #AC012305.7, coordinates
78,323–78,502.
Southern Blot Analysis
For Southern blot analysis, restriction-digested
DNA was electrophoresed through a 0.8% agarose
gel and transferred to Zeta-Probe GT membranes
(Bio-Rad, Hercules, CA). Probes were labeled
with 32P dCTP by the random hexamer method
(Feinberg and Vogelstein, 1983). Probe hybridiza-
tion to membrane was carried out overnight at
688C in 10 mL of ExpressHyb (Clontech); mem-
branes were then washed for 15 min at 68C in
0.3 SSC/0.1% SDS, and the results were visual-
ized with the Storm 840 phosphoimage system
(Molecular Dynamics, Sunnyvale, CA). Probe A
was derived from the NCBI chromosome 18
contig, accession #NT_010966.13, coordinates
30,787,107–30,786,164. Probe B also was derived
from the NT_010966.13 contig, coordinates
30,682,148–30,681,194. The cytogenetic locations
of probes A and B relative to BID-CHR18 are indi-
cated in Figure 1A. Both probe A and probe B were
synthesized by PCR and sequenced to conﬁrm
their identities.
Northern Blot Analysis
Total RNA was isolated from the indicated cell
lines according to the cesium chloride/guanidium
isothiocyanate method (Sambrook et al., 1989).
RNA was resolved on a 1 MOPS gel by electro-
phoresis and transferred onto a NYTran membrane
(Schleicher and Schuell BioScience, GmbH, Dassel,
Germany). DNA probes were labeled with 32P
dCTP by the random hexamer priming method.
Blots were hybridized at 428C in UltraHyb
(Ambion, Austin, TX). The membrane was washed
in 0.1 SSC/0.1% SDS at 608C and exposed to ﬁlm
at 708C using intensifying screens. After SMAD4
hybridization and exposure, the membrane was
stripped by boiling for 30 sec in 0.1 SSC/0.1%
SDS before being hybridized with the beta actin
probe. The SMAD4 probe was constructed by
EcoRI and PstI restriction digest of the SMAD4-
FLAG plasmid and isolation of the 300-bp fragment
at the 30 end of the SMAD4 ORF. The beta actin
probe was described previously (Wu et al., 1999).
Reverse Transcription Polymerase Chain Reaction
cDNA was synthesized from 5 mg of the whole
RNA template with random primers and Super-
Script II RNase H Reverse Transcriptase
(GibcoBRL) according to the manufacturer’s
instructions. Human breast RNA was acquired
from Invitrogen, human fetal brain RNA from
Stratagene (La Jolla, CA). Professor V. Band, of the
Radiation Oncology Department of New England
Medical Center, provided RNA from the human
mammary epithelial cell cultures 70N and 76N
and the transformed breast cell cultures 70E6 and
76E6 (Wazer et al., 1995). PCR primers hed1R and
hed3F amplify a cDNA product spanning exons 2–
4 of the DCC transcript. Cyclophilin A was chosen
as a housekeeper control, as a recent report indi-
cated it is present at low copy number in both nor-
mal and cancerous breast tissue (Tricarico et al.,
2002). Primers CYCA-F1 and CYCA-R1 amplify a
cDNA product that includes exons 1–5. The cyclo-
philin A and DCC reverse transcription polymer-
ase chain reaction (RT-PCR) products were
sequenced to conﬁrm their identities.
Western Blot Analysis, Immunoprecipitation,
and Antibodies
Protein lysates (25 mg) were resolved with 4%–
20% Tris-glycine gels (Invitrogen) and transferred
onto Immobilin-P membranes (Millipore, Bedford,
MA). For immunoprecipitation with M2-FLAG
antibody agarose beads (Sigma-Aldrich, St. Louis,
MO), the cells were lysed in a buffer containing
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10%
Figure 1. The HCC-1428 genome has a biallelic deletion of 260–
330 kbp between tumor-suppressor genes SMAD4 and DCC. (A) PCR
sequence-tagged site (STS) map of the 260–330 kbp BID-CHR18 dele-
tion (human chromosome 18 centromere to the left, 18q telomere to
the right; control PCR fragment is from chromosome 2; accession no.
AC012305.7, coordinates 78,323–78,502; T, HCC-1428; N, HCC-1428
BL). (B) Southern blot analysis conﬁrms BID-CHR18 deletion. Probe A
spans STS 84-2. The location of probe B relative to BID-CHR18 is indi-
cated in panel A (Bgl, BglII; Eco, EcoRI; Hind, HindIII; Pst, PstI). (C)
Sequence analysis demonstrates two alleles of single-nucleotide poly-
morphism rs2615548 in HCC-1428 BL genome, both deleted from the
HCC-1428 genome. The control PCR fragment is identical to the panel
A control.
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glycerol, 1% triton, 2 mM EDTA protease inhibi-
tor cocktail set I (CalBiochem, San Diego, CA),
1 mM Na3VO4, and 40 mM NaF. The beads were
precipitated, resuspended in Laemmli sample buf-
fer, and subjected to immunoblot analysis. The
primary antibodies used in this study were
mouse monoclonal:B-8, for Smad4 (Santa Cruz
Biotechnology, Santa Cruz, CA); TU02, for tubulin
(Santa Cruz Biotechnology); M2-FLAG, for FLAG
(Sigma-Aldrich); JL-8, for GFP (Clontech); and
Hvin1, for vinculin (Sigma-Aldrich).
Plasmids
Full-length (normal) SMAD4 and D(49–51)-
SMAD4 cDNAs, from MCF7 and HCC-1428
cDNAs, respectively, were cloned into the C-
terminal FLAG expression vector pCMVTag4A
(NCBI accession no. AF073000; Stratagene). RT-
PCR was performed with Pfx Platinum Polymer-
ase (Invitrogen) according to the manufacturer’s
instructions. Thorough sequence analysis of
Smad4-FLAG and D(49–51)-Smad4-FLAG con-
ﬁrmed their identities.
Pulse Chase Analysis
COS-1 cells at 50% conﬂuence were transfected
with either the SMAD4-FLAG or the D(49–51)-
SMAD4-FLAG plasmids. For transfection, 5 mg of
plasmid and 60 mL of lipofectamine (Invitrogen)
per 75 cm2 ﬂask were used; each 75-cm2 ﬂask of
cells represented a time point in the pulse-chase
experiment. Forty-eight hours posttransfection, the
cells were placed in L-methionine- and L-cystine-
free DMEM and 5% dialyzed fetal bovine serum
with 35S-labeled L-methionine and L-cystine at 180
mCi/mL for 2 hr at 378C/5% CO2 (Amersham Bio-
sciences, Piscataway, NJ). Chase with cold
L-methionine and L-cystine was carried out for the
speciﬁed periods. Sequential immunoprecipitation
with M2-FLAG antibody agarose beads was per-
formed twice before the labeled protein was
resolved on a 4%–20% Tris-glycine gel according to
standard protocols (Struhl, 2001). After drying, the
gels were placed between 6-mm-thick single layers
of Standard Mylar(Somar International Inc., Sparks,
NV), exposed for 5–7 days to the LE storage phos-
phoimage screen (Amersham Biosciences), and the
images processed with the Storm 840 system.
Proteasome Inhibitors
MG-132 (Z-Leu-Leu-Leu-al) was purchased
from Sigma-Aldrich. PS-341 (also known as Borte-
zomib or Velcade) was a gift of Millennium Phar-
maceuticals (Cambridge, MA).
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was
performed by standard methods on metaphase cells
prepared from the HCC-1428 cell line. A Spectrum
Orange-labeled CEP18 centromeric probe and
a SpectrumGreen-labeled chromosome 18 paint
probe (both obtained from Vysis, Downers Grove,
IL) was used in dual-color FISH. Fluorescence sig-
nals were captured after a DAPI counterstain on an
Applied Imaging Cytovision Imaging system
attached to a Nikon Eclipse 600 microscope.
RESULTS
Representational Difference Analysis Identiﬁed a
Novel Biallelic Deletion in the HCC-1428 Genome
The HCC-1428 RDA library provided 740 read-
able sequences, 62 of which (8.4%) represented
sequences present in the HCC-1428 BL genome
but absent in the HCC-1428 genome (Table 1).
One sequence, 84-2, perfectly matched NCBI
accession number AC027216.6, at chromosome
band 18q2.1, coordinates 49,580–50,359. Southern
blot analysis conﬁrmed deletion of this sequence
from the HCC-1428 genome (Fig. 1B).
To determine whether this novel deletion repre-
sented the somatic loss of two alleles, sequence
analysis of candidate SNPs was performed.
Sequence analysis of the HCC-1428 BL (paired
normal) PCR products of candidate SNP
rs2615548 revealed two alleles, G and T. Candi-
date SNP rs2615548 did not amplify from the
HCC-1428 genome (Fig. 1C). The deleted locus
was named biallelic deletion of chromosome 18,
BID-CHR18.
BID-CHR18 Spans 260–330 Kilobase Pairs and Is
Between Candidate Tumor-Suppressor Genes
SMAD4 and DCC
BLAST searches of the NCBI HTGS and NR
databases mapped BID-CHR18 to NCBI acces-
sion number AC027216.6, at chromosome band
18q21.1. PCR radiation hybrid mapping of the 84-
2 fragment with the Stanford G3 Human/Hamster
RH Panel also localized the deletion to 18q21.1,
within 5 cM, or about 100 kbp, of STS SHGC-
7133. A physical map of the deletion was
constructed with publicly available STSs and the
NCBI HTGS and NR databases. The centromeric
end of the deletion was determined to within 40
kbp. SHGC-105608, at AC027216.6, coordinates
109,631–109,933, did not PCR-amplify from
the HCC-1428 genome, whereas stSG28163, at
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AC027216.6, coordinates 150,505–150,627, did
amplify from the HCC-1428 genome (Fig. 1A).
To map the telomeric extent of the deletion, we
performed a PCR screen of a human BAC library
for SHGC-7133 isolated BAC 494J9. STS 494J9
SP6, present in the HCC-1428 genome, maps to
NCBI accession number AC105032.4, coordinates
22,666–22,965. Overlap of AC105032.4 with NCBI
accession number AC080051.6 and a novel STS
we generated from the latter, 800–20K, localized
the telomeric extent of BID-CHR18 to 27 kbp
between 800–20 K and 494J9SP6 (Fig. 1A). Ulti-
mately, sequence information from NCBI acces-
sion numbers AC027216.6, AC022701.6, and
AC080051.6, as well as from the UCSC human
genome server, July 2003 freeze, allowed us to con-
clude that BID-CHR18 is 260–330 kbp in size and
between candidate tumor suppressors SMAD4 and
DCC (Fig. 1A).
We performed a PCR screen of STSs SHGC-
7133 and 84-2 on a panel of 40 breast cancer cell
line genomes and 40 breast cancer xenograft
genomes. Both SHGC-7133 and the 84-2 fragment
ampliﬁed in all 80 genomes (results not shown).
Bioinformatic Analysis of BID-CHR18 Revealed
No Known Genes
BID-CHR18 is unremarkable, save for its paucity
of known coding sequence. No known genes or
spliced expressed sequence tags (ESTs) are con-
tained in BID-CHR18 as assessed by BLAST
searches and analysis with the UCSC human
genome browser, April 2003 freeze. BID-CHR18
has no known microRNA genes. We performed
Paracel BLAST (Paracel Inc., Pasadena, CA) of
BID-CHR18 (using accession nos. AC027216.6,
AC022701.6, and AC080051.6) versus 1,138 candi-
date chromosome 18 exons found by trap analysis
(Chen et al., 2003). This approach identiﬁed three
putative exons, NCBI accession nos. BH608849,
BH608723, and BH608687, within BID-CHR18.
However, repeated exon connection RT-PCR reac-
tions on human fetal brain, fetal testis, and breast
cDNA templates failed to amplify the spliced tran-
scripts containing these sequences.
BID-CHR18 contains an unexceptional number of
human–mouse orthologous regions. BID-CHR18
(April 2003 UCSC freeze) was compared to the cor-
responding mouse region (February 2003 UCSC
freeze) with the VISTA 2.0 browser. This approach
revealed 51 regions of 50 bp or more that had more
than 90% nucleotide identity between human and
mouse. All human–mouse hits were checked for
synteny and best possible matches. The similar
regions covered a combined 4,998 bp, or 1.5% of the
maximum possible (*330 kbp) BID-CHR18. This is
consistent with the ﬁndings of the Mouse Genome
Sequencing Consortium, which concluded that
roughly 2.3% of the human genome is conserved in
the mouse in small segments (50 bp) that are not
coding sequences, 50 UTRs, 30 UTRs, or repeats
(Waterston et al., 2002). There is synteny of the
SMAD4-(BID-CHR18)-DCC arrangement between
humans and mice. However, this also was expected
because 90% of the human genome shows synteny
with the mouse genome (Waterston et al., 2002).
RepeatMasker analysis of the BID-CHR18 dem-
onstrated that 49% of the deleted sequence repre-
sents interspersed repeats. Speciﬁcally, BID-
CHR18 consists of 7.5% SINEs, 27.3% LINEs,
11.3% LTR elements, and 3.4% DNA transposon
elements. These proportions are very similar to
the average number of human genome–wide inter-
spersed repeats: 44% combined, 13% SINE
sequences, 20% LINE sequences, 8% LTR
sequences, and 3% DNA transposon elements
(Lander et al., 2001).
BID-CHR18 Is in the 50 Extension Intergenic
Region of DCC
The BID-CHR18 deletion does not extend into
the DCC ORF of the HCC-1428 genome (Fig. 1A).
At *300 kbp, the apparently gene-barren BID-
CHR18 constitutes part of a large intergenic
region upstream of DCC. The 350 kbp between
the ﬁrst exon of DCC and BID-CHR18 lack any
known genes or spliced ESTs, meaning that DCC
has a 50 extension intergenic region of at least 700
kbp (distance from the 50 end to the nearest
upstream gene). In contrast, a recent analysis of 50
extension intergenic regions found medians of 46
and 18 kbp for chromosomes 21 and 22, respec-
tively (Chen et al., 2002).
RT-PCR analysis detected DCC transcripts in
human fetal brain and adult breast cDNAs;
TABLE 1. Results of Representational Difference Analysis






AF152363, 164,476-614,775 (FRA3B) 15 (2%)
HS4B958RAJ, 87,072-87,423 (EBV) 18 (2.4%)
AC027216.6, 49,960-50,298 (#84) 29 (3.9%)
All fragments not present in
the HCC-1428 genome
62 (8.4%)
Fragments detected by RDA process 740 (100%)
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sequence analysis of these PCR products con-
ﬁrmed their identity. The DCC cDNA did not
amplify from the HCC-1428 cDNA, nor did it
amplify from nontransformed, cultured breast epi-
thelial cells HMEC, 70N, and 76N cDNAs, possi-
bly because of dedifferentiation of breast cells in
culture (Fig. 2F). Western blot analysis of the
DCC protein failed to detect it in the HCC-1428
or other breast cancer cell lines or cultures (results
not shown).
The HCC-1428 18q21.1 Band Also Contains
a Biallelic Deletion at SMAD4
Northern blot analysis demonstrated that the
SMAD4 message was not disrupted in the HCC-
1428 cell line (Fig. 2D). However, sequence analy-
sis of SMAD4 in the HCC-1428 genome revealed
only an allele with a 9-bp deletion of exon 1 ablating
amino acids 49, 50, and 51 (Fig. 2C). Sequence anal-
ysis of the entire ORF, 50 UTR, and 30 UTR of the
HCC-1428 SMAD4 gene uncovered no additional
mutations. The mutation was conﬁrmed in the
SMAD4 transcript of the HCC-1428 cell line. The
normal SMAD4 exon 1 sequence did not amplify
from the HCC-1428 genome, indicating that both
normal copies of SMAD4 exon 1 had been lost from
the HCC-1428 genome (Fig. 2B). In addition, West-
ern blot analysis demonstrated that endogenous
mutant SMAD4 protein was almost undetectable in
the HCC-1428 proteome (Fig. 2E). This SMAD4
mutation was named, in line with the guidelines
of the HUGO Mutation Database Initiative in
genomic DNA, cDNA, and protein contexts,
g.144_152del, c.144_152del, and p.Glu49_Lys51del,
respectively (den Dunnen and Antonarakis, 2000),
referred to henceforth as D(49–51)-SMAD4.
D(49–51) Mutation Enhanced SMAD4
Protein Degradation
Western blot analysis demonstrated that endoge-
nous D(49–51)-SMAD4 protein was almost unde-
tectable in the HCC-1428 proteome (Fig. 2E). To
explore the effect of D(49–51) on the steady-state
level of SMAD4 protein, we transfected normal
SMAD4-FLAG and D(49–51)-SMAD4-FLAG con-
structs into COS-1 cells. Immunoprecipitation
was needed to detect the mutant SMAD4-FLAG
protein, which was found to have a much lower
steady-state level than did normal SMAD4-FLAG
(Fig. 3A). To determine whether D(49–51) de-
creased SMAD4 protein synthesis or stability, we
transfected normal SMAD4-FLAG and D(49–51)-
SMAD4-FLAG plasmids into COS-1 cells and
performed pulse chase analysis. A 2-hr pulse labels
similar amounts of normal and mutant protein. In
this assay, labeled SMAD4-FLAG was stable for
18 hr, but D(49–51)-SMAD4-FLAG had a half-life
of less than 4 hr (Fig. 3B).
Proteasome Inhibition Increased the Level
of Exogenous and Endogenous D(49–51)-SMAD4
in HCC-1428 Cells
To characterize the mechanism of the enhanced
degradation of D(49–51), COS-1 cells trans-
fected with normal SMAD4-FLAG and D(49–51)-
SMAD4-FLAG were incubated with MG-132, a
26S proteasome inhibitor. A concentration of
50 mM was needed to observe even modest stabili-
zation at 4 hr (Fig. 3A). At this concentration, MG-
132 is toxic to COS-1 cells, leading to a dramatic
decrease in normal SMAD4-FLAG after more than
4 hr (not shown). However, 24-hr treatment of
HCC-1428 cells with the proteasome inhibitors
MG-132 (10 mM) or PS-341 (100 nM) caused a
dramatic increase in the level of endogenous
D(49–51)-SMAD4 protein (Fig. 3C).
Chromosome Paint Analysis Demonstrated an
Unbalanced Translocation of Chromosome Arm
18q in HCC-1428 Cells
FISH, using orange chromosome 18 centromeric
and green chromosome 18 paint probes, was per-
formed on HCC-1428 to determine the structure
of chromosome 18. The analysis of HCC-1428 cells
identiﬁed one intact chromosome 18 in all cells
and an unbalanced chromosome 18 translocation,
with the proximal half of 18q detected, making a
net loss of one copy of distal 18q21 material (Fig. 4).
Therefore, only one allele of chromosome 18 is
present in the SMAD4-BID-CHR18-DCC interval.
DISCUSSION
Frequent loss of speciﬁc chromosome arms
often is interpreted as representing loss of cano-
nical, genetic two-hit tumor-suppressor genes.
Potential candidate tumor-suppressor genes for
human chromosome arm 18q include SMAD4 and
DCC. However, neither SMAD4 nor DCC has a fre-
quency of mutation of both alleles approaching
that of the observed LOH and CGH in breast can-
cer. The rate of loss of both SMAD4 alleles, as
judged by immunohistochemistry, is 2% in spora-
dic breast cancer (Xie et al., 2002). Only one case
of mutation of both SMAD4 alleles has been
reported previously in breast cancer (Schutte et al.,
1996). A two-hit lesion of DCC has never been
documented in breast cancer.
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The relevance of DCC to tumor suppression is a
topic of much controversy. DCC was ﬁrst identiﬁed
as a candidate tumor-suppressor gene by virtue of
its position in a biallelic deletion in a colon tumor
genome (Fearon et al., 1990). However, character-
ization of biallelic deletions of the DCC locus in
cancer demonstrated that these lesions were
always intergenic, never limited to the DCC gene
itself. Indeed, some reported DCC deletions
include the BID-CHR18 locus (Hilgers et al.,
Figure 2. The HCC-1428 SMAD4 locus contains a 9-bp deletion
mutation in exon 1. (A) Schematic diagram of SMAD4 gene [above,
exon/intron structure; below, position of D(49–51) mutation relative to
domains of SMAD4; MH1, mad homology 1 domain, responsible for
sequence-speciﬁc DNA binding; MH2, mad homology 2 domain,
involved in heteromerization and transactivation (Miyaki and Kuroki,
2003); amino and carboxy terminal residues indicated as 1 and 552,
respectively]. (B) PCR of SMAD4 exon 1 from HCC-1428 genome
ampliﬁes only a truncated product. (C) Sequence analysis reveals a 9-bp
deletion from exon 1 of SMAD4 of HCC-1428 (nucleotides deleted
from HCC-1428 BL genome in box, deleted amino acids in boldface).
(D) Northern blot analysis of SMAD4 transcript demonstrates normal
level in HCC-1428 cells compared to human breast tissue and other
breast cancer cell lines (breast, whole RNA from human breast tissue;
Hm, human mammary epithelial cell culture; MDA-MB-468, negative
control). (E) Western blot analysis of human cancer cell lines shows
greatly attenuated SMAD4 protein in HCC-1428 cells (SW-480 and
MDA-MB-468, negative controls). (F) RT-PCR does not amplify DCC
cDNA from HCC-1428 or cultured human breast cells (FB, fetal brain
cDNA template; Br, human breast tissue; Hm, human mammary epithe-
lial cell culture).
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2000). No convincing somatic missense, nonsense,
frameshift, or in-frame deletion mutations of the
DCC ORF have been reported in the literature
(Cho et al., 1994; Miyake et al., 1994). Inherited
mutation of DCC also has been excluded as predis-
posing to hereditary colon cancer (Peltomaki et al.,
1991). Finally, transgenic mice heterozygous for a
DCC knockout allele are not predisposed to colon
cancer (Fazeli et al., 1997). Nonetheless, immuno-
histochemical studies indicated that DCC protein
is absent in a subset of a variety of cancers includ-
ing breast cancer (Koren et al., 2003). The pres-
ence of DCC protein has been shown to be a
positive prognostic factor in stage II and stage III
colorectal carcinoma (Shibata et al., 1996), and
overexpression of Netrin-1, a DCC ligand, stimu-
lates the formation of adenocarcinoma in Apc
mutant mice (Mazelin et al., 2004).
In contrast to DCC, SMAD4 has been established
as a canonical two-hit tumor-suppressor gene.
SMAD4 has been shown to be biallelically deleted
from a variety of pancreatic carcinoma cell line and
xenograft genomes. Many of these deletions are
intragenic, eliminating only the SMAD4 gene
(Hahn et al., 1996b). Many somatic missense, non-
sense, and frameshift mutations have been reported
to occur in the SMAD4ORF in pancreatic and colon
carcinoma without concurrent ampliﬁcation of
normal the SMAD4 ORF sequence (Iacobuzio-
Donahue et al., 2004). Inherited mutated alleles of
SMAD4 are responsible for 50% of juvenile polypo-
sis syndrome cases (Howe et al., 1998). SMAD4
protein has not been detected in polyps that
develop in carriers of SMAD4 mutations, indicating
loss of the normal SMAD4 allele (Woodford-
Richens et al., 2001). Mice heterozygous for a
SMAD4 knockout allele are predisposed to gastric
polyposis, with loss of the normal SMAD4 allele in
subsequent carcinomas (Xu et al., 2000). The
SMAD4 protein probably acts as a tumor suppressor
through its signal transduction role in the TGFB
pathway (Massague et al., 2000).
The novel deletions described in this report are
true two-hit lesions. The normal paired genome
Figure 3. The D(49–51) mutation accelerates 26S proteasome–
mediated degradation. (A) Western blot analysis showing attenuated
expression of D(49–51)-SMAD4-FLAG versus SMAD4-FLAG in COS-1
cells [D-SMAD4-FLAG, D(49–51)-SMAD4-FLAG; MG-132, 50 mM MG-
132, 4 hr]. Experiment was performed 3 times. (B) Pulse chase analysis
demonstrating accelerated degradation of D(49–51)-SMAD4-FLAG ver-
sus SMAD4-FLAG in COS-1 cells [above, representative pulse chase
experiment; below, vertical axis; 35S SMAD4-FLAG as percentage of
signal at 0 hr; chase, average of 3 independent experiments; vertical
bars, standard error at each time point; D-SMAD4-FLAG, D(49–51)-
SMAD4-FLAG]. (C) Inhibition of the 26S proteasome rescues SMAD4
protein levels in HCC-1428 cells. Western blot analysis of endogenous
pD(49–51)-SMAD4 in HCC-1428, T47D (unmutated SMAD4), MDA-
MB-428 cells (SMAD4 biallelicly deleted) (MG-132, 10 mM MG-132,
24 hr; PS-341, PS-341, 24 hr).
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possesses two separate alleles at each deleted
locus; both were lost en route to oncogenesis.
Analysis of deletion maps from previous reports of
chromosome arm 18q deletion in human cancer
found complete (presumably biallelic) loss of BID-
CHR18 from other cancer cell lines and xenograft
genomes. Speciﬁcally, studies of SMAD4 (Hahn
et al., 1996a; Hilgers et al., 2000) and SMAD4 and
DCC (Thiagalingam et al., 1996) reported BID-
CHR18 deletion from genomes of cancer cell lines
and xenografts, although with the concomitant loss
of the respective candidate tumor-suppressor
genes. It therefore is possible that the phenotypic
consequences of these large deletions are in part a
result of the genetic information in BID-CHR18.
Other studies have identiﬁed homozygous dele-
tions centromeric to the SMAD4-BID-CHR18-DCC
interval (Thiagalingam et al., 1996; Takei et al.,
1998; Wilentz et al., 2000). Some of these deletions
reduced the SMAD4 message by affecting a non-
coding exon of SMAD4.
The putative relationship between DCC
expression in human breast epithelial cells with
the BID-CHR18 locus is difﬁcult to assess. Other
investigations have shown the DCC protein to be
breast in epithelia lining ducts and acini in vivo
by immunohistochemical techniques (Koren
et al., 2003). In our study, the DCC transcript was
detected in fetal brain and normal breast tissue,
but not in three separate normal breast epithelial
cell cultures or in HCC-1482 or other breast
cancer cell lines (results not shown). DCC
transcription appears to be down-regulated in
response to cell culture, independent of malig-
nant transformation. This phenomenon has been
observed by Thompson et al. (1993), who used
Northern analysis to detect DCC transcript in
breast cancer tumors and MCF-7 xenograft cells
but did not detect DCC transcript in MCF-7 cells
in culture or in the breast cancer cell lines MDA-
MB-231 and T-47D (Thompson et al., 1993).
Therefore, we cannot rule out that deletion of
Figure 4. Identiﬁcation of chromosomal dele-
tion of distal 18q in HCC-1428. A metaphase
with DAPI counterstain showing two centromeric
signals of chromosome 18 (Orange) and chromo-
some 18 painting (Green). White arrow indicates
the unbalanced chromosome 18 translocation
with deletion of distal of 18q.
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BID-CHR18 may have affected the expression of
DCC in the context of the primary tumor,
perhaps via elimination of a DCC enhancer
sequence. The deﬁnitive gene content of BID-
CHR18 is difﬁcult to assess with current resour-
ces, and it does not contain any currently known
genes.
The 9-bp D(49–51) SMAD4 mutation repre-
sents an additional two-hit lesion of the HCC-
1428 genome. No other in-frame 3-amino-acid-
deletion mutations have been reported in SMAD4
in sporadic cancer or juvenile polyposis (JP),
although one JP kindred has a 9-nucleotide
deletion that eliminates amino acids 64–66 and
adds a threonine (Woodford-Richens et al.,
2000). The D(49–51) SMAD4 mutation is in the
MH1 (Mad homology 1 domain) DNA-binding
domain. Based on a comparison with the crystal
structure of fellow SMAD protein family mem-
ber SMAD3, amino acids 49–51 are not directly
involved in DNA contact; however, SMAD4
missense mutations in the vicinity reduce DNA
binding in vitro (Moren et al., 2000).
Notwithstanding the DNA-binding impairment
conferred by MH1 cancer-speciﬁc mutations,
Moren et al. (2003) and others have convincingly
demonstrated that such lesions, speciﬁcally, L43S,
G65V, R100T, and P130S, all inactivate the
SMAD4 protein by enhancement of polyubiquiti-
nation and 26S proteasome–mediated degradation
(Xu and Attisano, 2000; Moren et al., 2003). Our
own pulse chase analysis of exogenous D(49–51)
SMAD4-FLAG protein and partial pharmacologic
rescue of endogenous D(49–51) SMAD4 by inhibi-
tion of the 26S proteasome conﬁrmed that this
mechanism is responsible for low levels of mutant
protein. Other recent studies have demonstrated
that the SMAD4 MH1 domain cancer mutants
R100T, G65V, and L43S have increased suscepti-
bility to ubiquitination and proteolysis mediated
by E3 ubiquitin ligase complex SCFskp2. Addi-
tional investigations are needed to conﬁrm that
D(49–51) SMAD4 also is targeted by the SCFskp2
complex (Liang et al., 2004).
Partial pharmacologic rescue of endogenous
D(49–51)-SMAD4 by inhibition of the 26S protea-
some conﬁrm that increased degradation was
responsible for the low level of SMAD4 protein,
not loss of any information from 18q21.1, the
deleted region, or elsewhere. This ﬁnding raises
the possibility that TGFB signaling attenuated by
SMAD4 mutation could be rescued in vitro or in
vivo by pharmacological inhibition of the 26S pro-
teasome.
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